Adapting the Elixhauser comorbidity index for cancer patients

CONCLUSIONSThe cancer‐specific Elixhauser comorbidity score performed as well as or slightly better than the cancer‐specific Charlson comorbidity score in predicting 2‐year survival. If the sample size permits, using individual Elixhauser comorbidities may be the best way to control for confounding in cancer outcomes research. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - February 1, 2018 Category: Cancer & Oncology Authors: Hemalkumar B. Mehta, Sneha D. Sura, Deepak Adhikari, Clark R. Andersen, Stephen B. Williams, Anthony J. Senagore, Yong ‐Fang Kuo, James S. Goodwin Tags: Original Article Source Type: research